Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis
Open Access
- 28 November 2022
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 34 (2) , 152-162
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- Merck Sharp and Dohme United Kingdom
This publication has 59 references indexed in Scilit:
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 InactivationCancer Research, 2012
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- A guide for functional analysis ofBRCA1variants of uncertain significanceHuman Mutation, 2012
- Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian CancerJAMA, 2011
- Secondary Somatic Mutations RestoringBRCA1/2Predict Chemotherapy Resistance in Hereditary Ovarian CarcinomasJournal of Clinical Oncology, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Preclinical mouse models for BRCA1-associated breast cancerBritish Journal of Cancer, 2009
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersNature, 2008
- The Concept of Synthetic Lethality in the Context of Anticancer TherapyNature Reviews Cancer, 2005
- Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype–phenotype correlationNature Genetics, 1995